Eascra Biotech develops proprietary Janus base nanoparticles (JBNps) for precision therapeutic delivery across challenging biological barriers like cartilage and solid tumors. These room-temperature stable nanoparticles effectively encapsulate and deliver diverse therapeutic cargoes, including siRNA, mRNA, and proteins. The platform supports applications in osteoarthritis treatment, cartilage regeneration, and targeted oncology with reduced systemic exposure.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Delivery of therapeutics to tissues like cartilage and solid tumors is challenging due to their dense extracellular matrix and poor vascularization. Traditional methods often result in insufficient drug concentrations at the target site and increased systemic exposure, leading to reduced efficacy and potential side effects.
Solution
Eascra Biotech develops Janus base nanoparticles (JBNps), a non-lipid, DNA-inspired synthetic molecule, for precision therapeutic delivery into hard-to-penetrate tissues. JBNps fully encapsulate therapeutic cargoes such as RNA, proteins, and peptides, rendering them room-temperature stable while maintaining bioactivity for extended periods. This targeted delivery approach enhances therapeutic efficacy in tissues like articular cartilage, kidneys, and ECM-rich solid tumors, while reducing systemic exposure and minimizing patient side effects. Eascra Biotech's technology addresses the limitations of conventional drug delivery methods, offering a versatile solution for various therapeutic needs, including osteoarthritis treatment, cartilage regeneration, and direct tumor therapy.
Target Audience
Eascra Biotech's primary customers are pharmaceutical and biotechnology companies focused on developing targeted drugs for musculoskeletal diseases, oncology, and regenerative medicine, as well as researchers in nanomedicine and drug delivery.
Features
- Janus base nanoparticles (JBNps) for targeted delivery of therapeutics
- Non-lipid, DNA-inspired synthetic molecule design
- Full encapsulation of therapeutic cargoes (siRNA, mRNA, Cas9, proteins, peptides, and other drug agents)
- Room-temperature stability of encapsulated cargoes
- Maintained bioactivity of cargoes for extended periods
- Versatile delivery to articular cartilage, kidneys, and ECM-rich solid tumors